Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Invested Capital (2017 - 2025)

Historic Invested Capital for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $265.5 million.

  • Autolus Therapeutics' Invested Capital fell 4434.56% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 4434.56%. This contributed to the annual value of $427.3 million for FY2024, which is 28334.05% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Invested Capital stood at $265.5 million, which was down 4434.56% from $346.5 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Invested Capital high stood at $582.0 million for Q1 2024, and its period low was $111.5 million during Q4 2023.
  • In the last 5 years, Autolus Therapeutics' Invested Capital had a median value of $284.9 million in 2022 and averaged $315.3 million.
  • Per our database at Business Quant, Autolus Therapeutics' Invested Capital plummeted by 6267.7% in 2023 and then skyrocketed by 28334.05% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Invested Capital stood at $313.3 million in 2021, then fell by 4.67% to $298.7 million in 2022, then plummeted by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then crashed by 37.88% to $265.5 million in 2025.
  • Its Invested Capital stands at $265.5 million for Q3 2025, versus $346.5 million for Q2 2025 and $371.1 million for Q1 2025.